A team of researchers from Taiwan has developed PanMETAI, an AI-powered platform that analyzes metabolic fingerprints in a ...

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

MPNs involve overproduction of blood cells, while MDS results in poorly formed cells, affecting blood cell function and counts. Diagnosis requires blood tests, bone marrow biopsy, and genetic testing ...

A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in diagnoses at later stages of the disease.

UC San Diego Health is the first health system in the country to offer a new blood test for testicular cancer, officials announced Monday. The test, a decade in the making, is being touted by UCSD ...

Expanded cohort reiterates strong adherence rate of over 90% for Shield blood-based colorectal cancer screening test Survey findings show eligible individuals prefer a blood test for colorectal cancer ...

UC San Diego Health is the first health system in the country to offer a new blood test for testicular cancer, officials announced Tuesday. The test, a decade in the making, is being touted by UCSD ...

Dec. 2 (UPI) --As new blood tests capable of detecting dozens of cancers in their early stages are hitting the market, disease prevention advocates say political and economic momentum is building for ...

When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...

Roche has claimed the exclusive international rights to Freenome’s multiomic cancer screening approaches, toward the goal of developing blood testing kits for markets outside the U.S. The licensing ...

Kentucky has one of the highest rates of colorectal cancer in the US, but early detection leads to a 91% five-year survival rate. Colorectal cancer is projected to become the leading cancer killer for ...